Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -6.40 -0.46% 1,383.60 1,386.60 1,387.20 1,391.40 1,373.20 1,380.60 21,110,506 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 14.7 69,420

Glaxosmithkline Share Discussion Threads

Showing 19176 to 19199 of 23075 messages
Chat Pages: Latest  779  778  777  776  775  774  773  772  771  770  769  768  Older
DateSubjectAuthorDiscuss
12/2/2019
16:41
Mylan did not waste any time.
zicopele
12/2/2019
16:36
WB: That's only possible when there is no original research cost
tradermichael
12/2/2019
16:35
Where is Monty when he is needed, telling us that he would buy Advair rather than the 70% cheaper generic? Probably on IAG telling everyone that hedging oil and lower oil price can both be beneficial simultaneously for airline stock
zicopele
12/2/2019
16:20
”Mylan launches generic version of Glaxo's Advair Diskus at 70% discount” Mylan N.V. (MYL +1.6%) announces the U.S. commercial launch of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), its generic version of GlaxoSmithKline's (GSK +0.4%) asthma and COPD med Advair Diskus. The company says its wholesale cost is 70% less that Glaxo's branded product and 67% less than its authorized generic. hTTps://seekingalpha.com/news/3432201-mylan-launches-generic-version-glaxos-advair-diskus-70-percent-discount#email_link
wbecki
12/2/2019
15:39
All the oil majors results were remarkable. They are cash generating machines. Even minnows like premier oil which are highly indebted are reducing debt. They have all seriously reduced cash cost per barrel equivalent. As for GSK. I am a buyer sub 1500.
zicopele
12/2/2019
15:35
In a way BP great results with oil down 21% last six months. That must have boosted IAG, I know they hedge so that also helps.
montyhedge
12/2/2019
15:01
I guess you have traded experian then. BP and IAG must be negatively correlated.
zicopele
12/2/2019
14:57
Yes BP good. But for traders like me, big bonus no stamp duty.
montyhedge
12/2/2019
14:53
So, I now have another 2420 shares in line for a 23p dividend (If I hold!)
tradermichael
12/2/2019
14:50
zico - yes, the day's low was 1541.60p and I was able to programme a buy with a limit of 1543.00p and it was 'bettered' at 1542.856 while I was away from the computer ….. ;0)
tradermichael
12/2/2019
14:49
You reckon Monty? I am long BP.
zicopele
12/2/2019
14:19
When the GSK President of global vaccines sells, even before ex dividend date, not that encouraging.
montyhedge
12/2/2019
14:07
Would have been just about the days low so well done on that. TM is one of the more credible posters on here that doesn't have a retrospective broker that others seem to use.
dr biotech
12/2/2019
14:05
I sold my GSK at 1560p see what happens, switched into IAG (British Airways) looks cheap to me and no stamp duty to pay, at least the Chancellor does not get it.
montyhedge
12/2/2019
13:55
I did not think they went that low yesterday. 1542?
zicopele
12/2/2019
08:20
I bought yesterday at 15.57pm, price 1542.856 …… ;0)
tradermichael
11/2/2019
22:20
Too high above £15
zicopele
11/2/2019
18:56
Could well be right. The damned thing has been very volatile share price wise for a blue chip company. I like the divi...but I hate looking at red on my portfolio. Watching and waiting....
funtimejonny
11/2/2019
18:13
After ex div I bet below 1500p, 1465p my target.
montyhedge
11/2/2019
17:14
I agree. It's a bit pricey right now. I have it on me watchlist but not buying at this price
funtimejonny
11/2/2019
11:45
Emma...you on first name terms TM? I do like your style. EMMA adds gravitas to your post. Meanwhile GSK is falling..it does tend to disappoint circa £16. Monty is right. Buy again sub £15.ex div. Leave the dividend for the longs. PS what is a green baseline?
zicopele
11/2/2019
11:33
The level and timing of GSK investments in Immuno-oncology is a strong indication that there's a massive opportunity here. Acquisition of Tesaro likely to tie in with the Merck partnership, and new R&D chief Hal Barron and Emma have it all planned with a faster track to the market than starting with a green baseline.
tradermichael
11/2/2019
10:59
A lot of hope and a lot of debt 20BN. GSK is not a corporate bond. A little bad news on the deep science of Tesaro and there goes your yield.
zicopele
11/2/2019
10:48
monty: "because I know when ex div, they always fall," Not always, and always not for long if it does!
tradermichael
Chat Pages: Latest  779  778  777  776  775  774  773  772  771  770  769  768  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201128 02:37:38